Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder / Maurizio Fava en The American Journal of Psychiatry, Año 2022 Vol. 179 - No. 2 (Febrero) 

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2022 Vol. 179 - No. 2 (Febrero) . - pp. 122-131 Título : Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder : a phase 2a randomized double-blind trial Tipo de documento: texto impreso Autores: Maurizio Fava, Autor ; Stephen M. Stahl, Autor ; Luca Pani, Autor Fecha de publicación: 2022 Artículo en la página: pp. 122-131 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos depresivos, Trastorno depresivo mayor, Neurología Resumen: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Link: ./index.php?lvl=notice_display&id=28331 [artículo] Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder : a phase 2a randomized double-blind trial [texto impreso] / Maurizio Fava, Autor ; Stephen M. Stahl, Autor ; Luca Pani, Autor . - 2022 . - pp. 122-131. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2022 Vol. 179 - No. 2 (Febrero) . - pp. 122-131 Palabras clave: Trastornos depresivos, Trastorno depresivo mayor, Neurología Resumen: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Link: ./index.php?lvl=notice_display&id=28331

---

1 (1 - 1 / 1)